Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 640.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
637.00 643.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.24 -22.87 -26.10 572
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 640.00 GBX

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Investors    Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
24/6/202117:59Silence Therapeutics (the old SR Pharma)50,328
08/8/201906:43Lets Short This Duffer Out Of Business704
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52
29/5/201310:32Silence Therapeutics - news and views1,412

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 17:29:08640.0025160.00O
2021-06-24 16:35:33638.64225,0001,436,935.50O
2021-06-24 15:35:20640.003,61623,142.40UT
2021-06-24 15:26:00643.0023147.89AT
2021-06-24 15:24:53637.0052331.24AT
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 640p.
Silence Therapeutics Plc has a 4 week average price of 600p and a 12 week average price of 492.50p.
The 1 year high share price is 680p while the 1 year low share price is currently 330p.
There are currently 89,398,841 shares in issue and the average daily traded volume is 63,579 shares. The market capitalisation of Silence Therapeutics Plc is £572,152,582.40.
wilko14: Yeah I’m almost as deep into ARWR as I am SLN. They’ve got loads of catalysts coming up and this wasn’t on anyone’s radar. Seems like bigger companies are starting to realise that this is a plug and play solution to their targets. Rather collaborate early than risk losing your market share to a superior and wholly owned solution. You can see that happening with Vertex and their AAT/CF franchises. SLN ripe to be picked up by BP.
wilko14: Welcome Back K, share price usually a rises when you start posting so I’m happy to see you.
1gw: The BP point is interesting. Someone on the $ARWR twitter feed linked this article (originally published in late 2018 and then slightly updated recently) which includes reference to how big pharma largely abandoned RNAi early on. hTtps:// You'd have to think some of them were ready to get back in given the results ALNY and ARWR are getting. For anyone with a cardiovascular focus, SLN must be tempting given SLN360 is wholly-owned. Astrazeneca and Takeda (and I suppose MNK) have the inside track, but (especially) if the driver is the RNAi platform rather than the particular drug then there should be plenty of other possibilities. Whether SLN would feel they would get "fair value" selling out at this point though is debateable.
1gw: I doubt SLN360 can overtake AMG890. While that gives the Arrowhead/Amgen drug a timing advantage (if it makes it to market) it also potentially allows SLN to learn from AMG890's results, in particular dosing amount and frequency. There is also the question of whether SLN can avoid (at least until after approval) a big cardiovascular outcomes study, and that also may be influenced by what AMG890 does. More generally, ARWR has a whole pile of data readouts coming through in the fairly near term (as well as lots of conference presentations) and that may influence how the market sees (and values) RNAi as a sector.
vonmoger: Beginning of October 19 the directors also went on a coordinated buying spree when the share price was below 2. Following that the share price basically doubled and then some in short order.
1gw: From the Annual Report remuneration section, Giles Campion and Iain Ross have really benefitted from share price appreciation through the LTIP. £1.2m "total remuneration" for Iain Ross and £0.98m total for Giles Campion (and I think that's just from June when GC joined the board). I note they forgot to update the major shareholder table on page 42, where end-2019 holdings are shown not end-2020 holdings. The end-2020 holdings are shown on the SLN website though.
vonmoger: Given the volumes in the US (still very low), difficult to make the argument that the new shares issued to new investors are providing additional liquidity. It appears to me, that other probably private investors, given the volumes are bidding up the US shares. It does not appear to me, that the new biotech investors are selling any meaningful number of shares with the share price up call it 20% in a week from the placing. Probably private investors to private investors... given the size of the transactions. This share is still as tightly held as ever... in increasing the liquidity of the shares the new listing so far has been a failure... it is doing alright for the share price though. I suspect we will need to be above GBP7 equivalent or higher to increase the volumes in the US share listing. Given the volumes in the UK this month.. I would assume there is still a healthy short interest via that SoL data to propel us higher. The US close and the UK open on Monday will be good to watch. I reckon I will be having a good laugh.
1gw: Yes, a bit of a surprise given their statements about non-dilutive funding. But then there were also those statements about negotiating with biotech investors. I make it around 548p/share equivalent, so if you look at the shareprice chart it does look rather as though the share price has been brought up to the desired placing price over the last 2-3 months, rather than falling to the placing price. It will be interesting to hear any spin they put on this at their next presentation, or if one comes out in analyst notes before that. Were they responding to demand from US institutions for ADS's given the awful liquidity on the Nasdaq listing, and effectively they've managed to get funding at a premium, which was what I guessed they might do if the biotech investors didn't bring anything but money? Or was it all done very quickly and opportunistically to take advantage of the recent tremendous strength in the shareprice? Either way, increasing the liquidity in the US listing must be a good thing. The shareprice only got above 500p, on this run, at the very end of December so getting a placing away at 548p is pretty impressive.
1gw: I've sold some in the 470's over the last few days, and may sell some more. I'm in year-end portfolio assessment mode and I have decided to bank some profit here on my 2nd-largest position after a spectacular year generally and a good one on SLN. If I look at all my buys and sells in SLN over the year, I've been relatively busy, putting through 116 transactions over 41 days. I've ended up losing a few % overall (average sell price / average buy price) due to being over optimistic about the near-term share price prospects after the Astrazeneca deal announcement and ahead of the Nasdaq listing. That loss is far outweighed (at this point) by the mark-to-market gain on my remaining position. Looking ahead to next year, I remain optimistic that it will be another good year, with particular hopes for a Takeda licensing deal early in the year and some good clinical read-outs from SLN124. The really big event for the year I think will come later with the first read-outs on SLN360. But this is biotech and as SLN is now a clinical biotech, there is the risk of major price downside should clinical readouts disappoint (e.g. SAE's, off-targeting, lower than expected knockdown), and that is a factor in my decision to take some profits here.
1gw: I can't speak for anyone else, but I own as many shares as I've ever owned. I first bought in in May 2016 (at 130p) and at the end of each calendar year I have owned more shares than at the end of the previous year each time with the exception of end-19 when I had reduced a bit as a result of profit-taking. Share prices have been: 130p May'16 100p End-2016 194p End-2017 52p End-2018 350p End-2019 400p Now So to date patience has paid off, even if anyone who managed to sell out at the peak would be happy right now. My frustration comes in part from thinking that the shareprice would have reacted better to the US listing, although if you look at say a 3-month chart of SLN vs ARWR and DRNA, SLN has done OK in relative terms. What has perhaps happened is that the US listing premium was reflected in SLN holding its price when the others were falling, and by the time we got to the actual listing that premium was pretty much fully built in. I've done very well (so far) on buying and selling ARWR, DRNA and ABUS and that also adds a bit to my current frustration with the SLN price. I also find the "artifical" prices frustrating. When the bid has popped up and I've tried to sell some, there seems to be no meaningful quantity available on my platforms at the apparent bid. And vv sometimes on the offer when I've tried to buy. It feels to me that there's not much depth to the bid or the offer and liquidity is perhaps worse now than before the US listing. Whether that means that something is brewing and some of the normal liquidity providers are now "inside" and so unable to trade, or whether it is just that attention is focused elsewhere in biotech (or other sectors) I have no idea. But the bull story hasn't changed for me, except perhaps that clinical risk is looming a bit larger. Now that we've had such a good year (deals, listing, first dosing, new CEO) we're perhaps in a bit of a lull ahead of the next deal (Takeda most likely?) and first clinical read-outs - and maybe that is making it easier for someone to mess around with the price, or perhaps some are taking profits. I have tried to sell some (without much success given the apparent poor liquidity) but overall I'm happy to keep a big position in the expectation that the price will recover in due course. As always, no advice intended. Please DYOR, this is early-stage biotech.
Silence Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 06:06:24